Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

Sunyu Kang(Harvard University), Eric H. Rubin(Rutgers Cancer Institute), Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), M A B Tice(Merck & Co., Inc., Rahway, NJ, USA (United States)), C. Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dinesh P. de Alwis(Merck & Co., Inc., Rahway, NJ, USA (United States))
Annals of Oncology
March 24, 2017
10.1093/annonc/mdx076
Cited by 106

Related Papers

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k